NCT00052611已完成2 期
Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 3
- 主要终点
- Response Rate Of PGE2
研究概览
简要总结
Patient at increased risk for developing a new head and neck squamous cell carcinoma are invited to take part in this study.
The investigators of this trial will attempt to study the effectiveness of Celecoxib in preventing cancer in patients who have oral leukoplakia and/or head and neck dysplasia.
详细描述
Celecoxib is being studied in precancerous lesions of the head and neck in part because, it has been shown to prevent the progression of another type of precancerous polyps (a type of abnormal growth) in patients at high risk for colorectal cancer. There are, however, no published studies yet looking at this drug in humans for the prevention of head and neck cancers. The U.S. Food and Drug Administration has approved celecoxib for arthritis and the prevention of polyps in patients with familial adenomatous polyposis (a type of precancerous syndrome in some families that can lead to colon cancer).
This study is being done to find out several things:
- Is celecoxib, also known by the trade name Celebrex ®, effective in reducing the expression of precancerous markers (biological signals for specific cellular activities) in oral leukoplakia and dysplasia (abnormal growth) of the oral mucosa?
- Is celecoxib effective in reducing the size of oral leukoplalda lesions and/or presence of dysplasia?
- Does the reduction in precancerous markers correspond with reduction of oral leukoplalda and/or presence of dysplasia?
- What are the side effects of celecoxib in this patient population?
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects will be ≥ 18 years.
- •Subjects will have oral leukoplakia on clinical examination and/or more than one previous HNSCC with dysplasia histologically proven on random biopsy within 6 months at the time of entry.
- •Patients who have had surgical treatment for a previous HNSCC, stage I-III, will be eligible for enrollment if they are cancer-free ≥ 9 months at the time of entry. Patients with CIS or new leukoplakia will be immediately eligible if they are more then 9 months from treatment of a prior carcinoma.
- •Leukoplakia lesions must be ≥ 0.5 cm in at least one dimension to be considered measurable. Measurable lesions are not required for entry.
- •The ECOG performance status will be ≤
- •(See Appendix B for ECOG performance status.)
- •The life expectancy will be ≥12 months.
- •Subjects will have adequate organ function with a platelet count of >100,000, ANC > 1500, PT and PTT < 1.5 X ULN, creatinine <1.5, urine protein <2+, and total bilirubin and liver transaminases <1.5 X ULN.
- •Premenopausal women will be required to use a reliable method of birth control throughout the course of therapy.
- •Subjects will provide written, voluntary informed consent
排除标准
- •Patients who have had surgical treatment for a previous HNSCC, stage I-III, will not be eligible for enrollment if they are cancer-free < 9 months at the time of entry.
- •Subjects with contraindication to nasopharyngoscopy and biopsy will not be enrolled.
- •Significant comorbidities, including known coronary artery disease, angina, history of myocardial infarction, congestive heart failure of at least grade 2 according to the New York Heart Association Criteria, advanced COPD requiring use of home oxygen, active alcohol abuse, bleeding diathesis, any history of gastrointestinal ulcer, acute or chronic renal insufficiency, or acute or chronic liver disease, will preclude enrollment in the trial.
- •Enrollment in the trial will be limited to patients who are free from current tobacco use. If the patient has a history of previous tobacco use, they Must be abstinent for at least 1 month prior to enrollment and meet the criteria established by the Food and Drug Administration for assessing smoking cessation, i.e. have not taken even a puff or taste of tobacco, including cigarette, cigar, pipe, chewing tobacco or other tobacco products, in the past 4 weeks.
- •Any active malignancy, except non-melanoma skin cancer, will preclude enrollment.
- •Persons who have taken full-dose aspirin, NSAIDs, COX-2 inhibitors and systemicallyabsorbed steroids, including inhaled steroids and nasal steroids other than mometazone, at least 3 times per week for 2 or more consecutive weeks within 3 months of enrollment will be excluded. Persons who have taken retinoids or selenium within 3 months of enrollment, or who have a history of anaphylactoid reaction to aspirin, NSAIDs or COX- 2 inhibitors will not be enrolled.
- •Persons taking ACE inhibitors will not be enrolled. Diuretics for CHF, or treatment with lithium or fluconazole will also preclude enrollment. Patients on coumadin will be required to have PT/INR monitoring BIW after starting celecoxib, until the patient is on a stable dose of coumadin for 7 days, and must have no contraindication to holding the coumadin for study biopsies.
- •Pregnant, lactating women or premenopausal women with a positive f3HCG will not be enrolled in the study.
研究组 & 干预措施
Celecoxib
Experimental
Celecoxib will be given at a pre-determine dose twice daily for 3 months. If there is a favorable change in biomarker expression on biopsy at 3 months, treatment will continue to complete a 12-month treatment period.
干预措施: Celecoxib (Drug)
结局指标
主要结局
Response Rate Of PGE2
时间窗: 2 years
次要结局
- Response Of Measurable Lesions(2 years)
- Change In SEB Expression Of Akt(2 years)
- Change In SEB Expression Of Ki-67(2 years)
- Change In SEB Expression Of COX-2(2 years)
- Assessing Safety(2 years)
- Change In SEB Expression Of BAX(2 years)
- Change In SEB Expression Of CD31(2 years)
- Change In SEB Expression Of BCL2(2 years)
- Change In SEB Expression Of VEGF(2 years)
研究者
Lori J. Wirth, MD
Wirth, Lori MD
Dana-Farber Cancer Institute
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
2 期
Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaNCT04643379Washington University School of Medicine30
进行中（未招募）
2 期
Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)Oral Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaNCT06009861Peking University Hospital of Stomatology110
已完成
1 期
Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck CancerHead and Neck CarcinomaNCT02718820Medical University of Vienna22
已完成
2 期
Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck CancerHead and Neck CancerNCT00713219Memorial Sloan Kettering Cancer Center14
招募中
2 期
Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckHead and Neck CancerNCT06725368Centre Paul Strauss46